October 2016, Volume 2, Issue 10

October 2016

Volume 2, Issue 10

This issue looks at the pros and cons of open-access publishing, features updates from the ASH Meeting on Hematologic Malignancies, and shares tips for incorporating small-group instruction.

Table of Contents

October 2016

A Primer on Email Etiquette

Saturday, October 1st, 2016
Every day, more than 200 billion emails are sent and received, for an average of 122 emails sent and received, per user, in a...

October 2016

ASH’s Sickle Cell Disease Coalition, new Hematologist podcast, and more

Saturday, October 1st, 2016
‘It Takes a Village … and We Need a Village’ Report on Sickle Cell Disease Suggests That Current State of Treatment and Care is Inadequate...

NIH and EPA to Study Link Between Chemical Exposure and Childhood Leukemia, ASH announces...

Saturday, October 1st, 2016
Andrew Kung Appointed Chairman of Pediatrics at Memorial Sloan Kettering Cancer Center Andrew L. Kung, MD, PhD, has been named the new chairman of the...

October 2016

Public Access: The Pros and Cons of Open-Access Publishing

Saturday, October 1st, 2016
Open access (OA), in which a scientific article is made freely available, in full, to anyone who wants to download it, seems at first...

Choosing Between Treatment Strategies for Patients With Acquired Hemophilia A

Saturday, October 1st, 2016
Acquired hemophilia A (AHA) is a rare bleeding disorder in which patients develop inhibitors against clotting factors – most often factor VIII (FVIII). For...

October 2016

Understanding Bone and Blood Marrow Transplants

Saturday, October 1st, 2016
Bone marrow is the soft tissue inside the bones that makes blood-forming cells known as blood stem cells. These grow into red blood cells...

Thinking Small

Saturday, October 1st, 2016
Anyone in medical education is familiar with Bloom’s Taxonomy, a pyramid-shaped model representing different types of learning objectives, from lower- to higher-order thinking (Figure...

Treating Myeloid Sarcoma After Induction Therapy

Saturday, October 1st, 2016
This month, Martin S. Tallman, MD, weighs in on the treatment for a patient with myeloid sarcoma after induction. You Made the Call! We asked,...

October 2016

Healthy Lifestyle, Family Support May Help Explain How Octogenarians Are Able to Live With...

Saturday, October 1st, 2016
In the 1970s, patients with sickle cell disease (SCD) were not expected to live into adulthood, but today, patients may live into their 40s...

Corticosteroids and Intravenous Immune Globulin Lead to Similar Outcomes in Pregnant Women With Immune...

Saturday, October 1st, 2016
Approximately 30 to 35 percent of pregnant women with immune thrombocytopenia purpura (ITP) require therapeutic intervention during pregnancy, frequently with either corticosteroids or intravenous...

NHLBI Releases Strategy for Heart, Lung, Blood, and Sleep Research

Saturday, October 1st, 2016
The National Heart, Lung, and Blood Institute (NHLBI) announced its Strategic Vision to chart the course of heart, lung, blood, and sleep research over the next...

FDA Grants Pracinostat Breakthrough Designation for Older Patients With AML

Saturday, October 1st, 2016
The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for pracinostat in combination with azacitidine for patients with newly diagnosed acute myeloid...

FDA Approves Blinatumomab for Pediatric Acute Lymphocytic Leukemia

Saturday, October 1st, 2016
The U.S. Food and Drug Administration (FDA) approved blinatumomab for pediatric and adolescent patients with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphocytic leukemia (ALL). The...

World Federation of Hemophilia Creates Universal Case Report Form for Hemophilia Patients

Saturday, October 1st, 2016
The World Federation of Hemophilia (WFH) created the Universal Case Report Form (U-CRF) to collect and standardize data on relevant diagnosis, therapies, and outcomes...

FDA Approves Ofatumumab Combination for Relapsed Chronic Lymphocytic Leukemia

Saturday, October 1st, 2016
The U.S. Food and Drug Administration (FDA) approved ofatumumab in combination with fludarabine and cyclophosphamide for patients with relapsed chronic lymphocytic leukemia (CLL). The approval...

ABIM and ACCME Partner to Produce CME Finder Tool

Saturday, October 1st, 2016
The American Board of Internal Medicine (ABIM) and the Accreditation Council for Continuing Medical Education (ACCME) partnered to produce the CME Finder – a web-based tool...

Cancer Moonshot Panel Releases List of Top 10 Ways to Fight Cancer

Saturday, October 1st, 2016
The Cancer Moonshot Initiative’s Blue Ribbon Panel, a 28-member panel of advisers that includes top cancer researchers and patient advocates, presented a report to...

PET–CT Adapted Treatment Strategy Identifies Hodgkin Lymphoma Patients Who Can Safely Escalate or De-Escalate...

Saturday, October 1st, 2016
Understanding the short- and long-term toxicity of therapies for Hodgkin lymphoma (HL) is important for guiding treatment decisions, especially for patients in which the...

Ipilimumab Induces Complete Responses in Patients Who Relapse After Allogeneic Transplantation

Saturday, October 1st, 2016
More than one-third of patients with hematologic malignancies who undergo allogeneic hematopoietic cell transplantation (alloHCT) will relapse, and treatment options for this patient population...

October 2016

Improving Risk Stratification in Standard-Risk Myeloma Patients: Age, Bone Marrow Involvement Independently Predict Survival

Saturday, October 1st, 2016
Though the field of multiple myeloma (MM) has seen many advances in treatment in the past two years – including three new drug approvals...

Adolescents and Minority Groups Underrepresented in Cancer Clinical Trials

Saturday, October 1st, 2016
Adolescent and young adult (AYA) patients, defined as those between the ages of 15 and 29 years, and non-white patients are often under-represented in...

TP53 Mutation Associated With Poor, But Varied, Outcomes in Myelodysplastic Syndromes

Saturday, October 1st, 2016
The TP53 mutation, a common molecular abnormality in myeloid malignancies such as myelodysplastic syndromes (MDS), is associated with poor outcomes; however, it is unclear...

SHARE